Clinical data
ATC code None
CAS Number 1092977-61-1 YesY
PubChem (CID) 25105689
ChemSpider 44208827
Chemical and physical data
Formula C16H26N2O2
Molar mass 278.38984 g/mol
3D model (Jmol) Interactive image

Evenamide (INN) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, that is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia.[1][2][3][4] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression.[3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.

See also


  1. "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
  2. Progress in Medicinal Chemistry. Elsevier. 6 October 2010. pp. 81–. ISBN 978-0-12-381293-3.
  3. 1 2 Satya Prakash Gupta (21 June 2011). Ion Channels and Their Inhibitors. Springer Science & Business Media. pp. 102–. ISBN 978-3-642-19922-6.
  4. Zuliani, Valentina; Amori, Laura; Rivara, Mirko (2011). "Advances in Design and Development of Sodium Channel Blockers": 79–115. doi:10.1007/978-3-642-19922-6_4.

This article is issued from Wikipedia - version of the 10/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.